Shares of Qiagen NV (NYSE:QGEN) have received an average recommendation of “Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $40.00.
QGEN has been the topic of several recent analyst reports. Barclays reaffirmed a “buy” rating on shares of Qiagen in a research note on Tuesday. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a research note on Monday, October 22nd. Deutsche Bank raised their price target on shares of Qiagen from $43.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, October 5th. Bank of America raised their price target on shares of Qiagen from $38.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday, August 2nd. Finally, Citigroup raised their price target on shares of Qiagen from $35.00 to $38.00 and gave the stock a “neutral” rating in a research note on Thursday, August 2nd.
QGEN stock opened at $35.56 on Friday. The stock has a market capitalization of $7.75 billion, a P/E ratio of 28.00, a P/E/G ratio of 2.09 and a beta of 1.10. Qiagen has a 12 month low of $30.20 and a 12 month high of $39.45. The company has a current ratio of 1.79, a quick ratio of 1.62 and a debt-to-equity ratio of 0.53.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Read More: Terms to Better Understand Call Options
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.